Muscular Dystrophy – Landscape & Forecast – Disease Landscape & Forecast

Muscular dystrophy (MD) is a spectrum of genetic disorders characterized by muscle weakness that, in severe forms, can lead to loss of ambulation and early mortality. Treatments are needed that can meaningfully delay or halt the progressive muscle degeneration associated with Duchenne muscular dystrophy (DMD), the most common childhood-onset form, as well as other forms of MD. The standard treatment for MD is glucocorticoids, which have proven effective in delaying the loss of ambulation. Recent conditional approvals of disease-modifying therapies (Sarepta’s Elevidys, Exondys 51, Vyondys 53, and Amondys 45; NS Pharma’s Viltepso; and PTC Therapeutics’ Translarna) have expanded treatment options for DMD patients, but there are lingering concerns about these drugs’ clinical efficacy. Additionally, many therapies with diverse mechanisms of action are in development for other forms of MD, including limb-girdle MD and Becker MD. Overall, the need for more-effective treatments for DMD and other forms of MD remains high.

Question answered

  • What are the sizes of the key MD patient populations in the United States and EU5, and how will these populations change through 2032?
  • What is the current treatment landscape for MD, and where are the greatest unmet clinical needs according to experts?
  • How well will pipeline therapies address current treatment gaps?
  • Which emerging therapies will launch before 2032, and what will be their commercial impact on the MD market through 2032?

Content highlights

  • Geographies: United States and EU5
  • Primary research: Six country-specific interviews with thought-leading neurologists supported by survey data collected for this study.
  • Epidemiology: Diagnosed prevalent and drug-treated cases of DMD, diagnosed prevalent cases of DMD by exon-skipping pattern and ambulatory status, diagnosed prevalent cases of other major MD subtypes such as Becker MD, limb-girdle MD, myotonic dystrophy, etc.
  • Forecast: Drug-level sales and patient share of key MD therapies through 2032.
  • Emerging therapies: Phase III / PR: 6 drugs; Phase I/II: > 10 drugs; coverage of select early-phase and preclinical products.

Product description

Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement

Niche & Rare Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

launch Related Market Assessment Reports